ProQR Therapeutics N.V.

As of June 30, 2026, ProQR Therapeutics N.V. carries a market capitalization of 228.76M, placing it among publicly traded companies globally. Its enterprise value stands at 126.94M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

ProQR Therapeutics N.V.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, ProQR Therapeutics N.V. has 141.12M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 9.35, and the price-to-book ratio stands at 2.88.

These figures are as of June 30, 2026. The EV/Sales ratio of 6.91 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 126.94M versus a market cap of 228.76M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, ProQR Therapeutics N.V. maintains a current ratio of 3.49, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, ProQR Therapeutics N.V. posted a negative return on equity (ROE) of -57.40, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -31.01, reflecting losses generated across the asset base. The company generates approximately 101,014.99 in revenue per employee across its workforce of 181.78, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, ProQR Therapeutics N.V. recorded 26,000.00 in income tax expense. The company reported a pretax loss of -42.01M and -42.04M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, ProQR Therapeutics N.V.'s stock has declined approximately 49.54% over the past 52 weeks. The 50-day moving average sits at 1.61, while the 200-day moving average is 1.48.

Over the twelve months ended June 30, 2026, ProQR Therapeutics N.V. generated 18.36M in revenue and converted that into -42.04M in net income, yielding earnings per share of -0.40. EBITDA reached -40.10M, while operating income came in at -42.85M.

As of June 30, 2026, ProQR Therapeutics N.V. holds 117.13M in cash and equivalents against 15.31M in total debt, resulting in a net debt position of -112.11M. Total book value stands at 79.48M, with working capital of 86.76M providing operational flexibility.

ProQR Therapeutics N.V. produced -49.01M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.15M in capital expenditures, free cash flow totaled -50.16M - equivalent to -0.47 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -233.37 and net profit margin of -228.93 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -29.21: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -20.65, meaning ProQR Therapeutics N.V. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, ProQR Therapeutics N.V. has an Altman Z-Score of -2.71, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.